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Administration of Vitamin C in a Patient with Herpes Zoster
- A case report -
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Herpes zoster as a result of reactivated varicella-zoster virus is characterized by vesicular eruptions on skin 
and painful neuralgia in the dermatome distribution. Pain during an acute phase of herpes zoster has been 
associated with a higher risk of developing postherpetic neuralgia. The current therapies for herpes zoster 
including analgesics and sympathetic nerve block as well as antiviral agents are important to alleviate pain 
and prevent postherpetic neuralgia. However, in some cases, the pain does not respond well to these treatments. 
We had a case in which a patient with herpes zoster did not respond to conventional therapy so we attempted 
to administer intravenous infusion of vitamin C which resulted in an immediate reduction in the pain. (Korean 
J  Pain  2011;  24:  108-111)
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    Herpes zoster (HZ), commonly called shingles, is a lo-
calized disease that results from the reactivation of the 
varicella-zoster virus that persists in a latent form in the 
dorsal root ganglia. It is characterized by vesicular erup-
tions  in  the  dermatome  distribution  followed  by  painful 
neuralgia [1]. 
    HZ may progress to postherpetic neuralgia (PHN) 
which is defined as pain along the cutaneous nerves per-
sisting  for  more  than  30  days  after  the  lesions  have 
healed. It is very difficult to manage PHN which negatively 
impacts quality of life [2]. Therefore this complication is 
the most conclusive reason to treat HZ. The current thera-
pies for HZ include analgesics and sympathetic nerve block 
as well as antiviral agents [3,4]. 
    Recent published reports show that the infusion of vi-
tamin C was effective in zoster-associated neuralgia [5,6]. 
In addition, it was reported that intravenous infusion of vi-
tamin C improved HZ [7]. In our case report, we described 
a patient with HZ who reported an immediate reduction in 
pain after intravenous administration of vitamin C. 
CASE  REPORT
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tory of localized zoster in the right occipital area. Skin 
rash developed on the right occipital area of the second 
and third cervical dermatome. Three days after the ap-
pearance of the rash, she was diagnosed with HZ by a 
dermatologist and was prescribed 5 mg of oxycontin twice 
a day, 650 mg of acetaminophen twice a day, 75 mg of 
pregabalin twice a day, and 500 mg of famciclovir 3 times 
a day, for 7 days, respectively. In spite of the 7-day ad-
ministration of these medications, her pain was rated at 
an intensity of 7 on the visual analogue scales (VAS) from 
0 (no pain) to 10 (worst pain imaginable) at first visit to 
our department. She suffered from constant aching pain 
along with intermittent, spontaneous, sore and shooting 
pain over the right occipital area, which was provoked by 
brushing. 
    Therefore, right stellate ganglion block (SGB) using 7 
ml of 1% lidocaine with ultrasound was performed but it 
did not reduce the symptoms. 30 minutes after SGB, 2 g 
of vitamin C was administered intravenously, but it also did 
not alleviate her pain. 
    On the second da y, a second attem p t of righ t SGB w as 
performed without any reduction in pain. 30 minutes after 
SGB, 4 g of vitamin C was administered intravenously, and 
then, the patient reported immediate pain relief from a 
VAS  of  7  to  2.  During  the  first  12  hours,  intermittent 
shooting pain and constant aching pain were maintained 
at a reduced intensity, but constant aching pain increased 
to a VAS of 5 again after 12 hours, while shooting pain 
remained constant at a V AS of 2. On the third day after 
right SGB, the pain did not decrease in intensity. But 30 
minutes after SGB, 4 g of vitamin C administered intra-
venously  sequentially  reduced  the  constant  aching  pain 
from a VAS of 5 to 2, which was maintained for about 12 
hours. However, there was no intermittent shooting pain 
after the administration of the vitamin C on the third day. 
On the fourth day, right SGB and sequential intravenous 
injection of 4 g of vitamin C was done just like before. 
Immediately after the administration of the vitamin C, she 
rated her pain intensity from a VAS of 4 to 1, which was 
maintained for about 12 hours. On the fifth day, intra-
venous injection of 4 g of vitamin C was done without SGB. 
Immediately after the administration of the vitamin C, she 
rated her pain intensity from a VAS of 4 to 0. Since then, 
her pain intensity has been maintained at a V AS of 0-1. 
The administration of 5 mg of oxycontin twice daily and 
650 mg of acetaminophen twice daily was stopped. Then 
she was discharged with a prescription for 75 mg of pre-
gabalin twice a day and 1 g of vitamin c twice a day. Five 
days after taking the pregabalin and vitamin C, she re-
ported a complete resolution of the pain and stopped tak-
ing the medication. At 3 months follow-up, she continued 
to have no pain without any complications.
DISCUSSION 
    Herpes zoster is a result of the reactivation of the la-
tent varicella-zoster virus within the dorsal root ganglia 
(DRG) or cranial nerve ganglia under various conditions re-
lated to a decrease in cell-mediated immunity [1]. Replication 
of the virus results in nerve injury and produces debilitat-
ing pain preceding the skin eruptions such as rashes or 
vesicles in the corresponding dermatome.
    The most common complication of HZ is PHN, which 
is defined as pain persisting for more than a month after 
healing of the rashes from acute HZ. PHN is notoriously 
difficult to treat and often is accompanied by physical and 
social disabilities and even psychological distress [8]. 
    The genesis of the pain during acute HZ is thought 
to be from inflammation and damage to the DRG and pe-
ripheral nerves. The inflammatory changes in the DRG can 
reduce intraneural blood flow, leading to hypoxia and en-
doneurial edema. This process finally causes neural injuries 
that can lead to the development of neuropathic pain. In 
addition, inflammatory changes in the dorsal horn produce 
nociceptor excitation and sensitization that cause central 
hyperexcitability [9,10]. In other words, uncontrolled per-
sistent pain in acute  phase may  finally  lead  to  chronic 
neuropathic  pain;  therefore,  faster  resolution  of  in-
flammation and pain is important [10].
    The incidence of PHN increases with the increasing 
age of the patient. In this case, the 67-year-old patient 
was at risk of developing PNH. She received drug treat-
m e n t  i n c l u d i n g  a n  a n t i v i r a l  a g e n t ,  a n t i c o n v u l s a n t ,  a n d  
analgesics. In addition to the drug therapies, SGB was tried 
for symptomatic relief in the acute phase of HZ and for 
the prevention of PHN [3]. Pregabalin medication has been 
shown to decrease significantly postherpetic neuralgia af-
ter the first day of treatment [11]. Our patient reported 
pain relief immediately after intravenous administration of 
vitamin C despite no relief after 7-days of administrating 
pregabalin and other drugs. Therefore, we presume that 
the vitamin C might be responsible for the pain relief.110 Korean J Pain Vol. 24, No. 2, 2011
    Vitamin C is a first line plasma antioxidant in vi-
rus-specific cellular immunity. A community-based case 
control study revealed that those with low vitamin C intake 
were significantly at higher risk for HZ [12]. Plasma vitamin 
C concentrations have been suggested to be related to pain 
modulation for intractable PHN [5,6]. In addition, vitamin 
C has been reported to reduce the prevalence of complex 
regional pain syndrome (CRPS) after foot and ankle sur-
gery [13]. Therefore, it has been proposed that it may be 
beneficial to supply and increase plasma concentrations of 
vitamin C for patients at high risk for CRPS [13,14]. 
    The mechanisms of neuropathic pain like zoster- 
associated  pain  and  CRPS  include  neuroinflammation, 
central  sensitization,  disinhibition,  and  reactive  oxygen 
species (ROS) [15,16]. Recent studies have suggested that 
ROS which are produced from peripheral inflammation will 
sensitize nociceptors so that they not only respond more 
vigorously to noxious stimuli but also start to respond to 
normally subthreshold stimuli. This peripheral sensitization 
n o t  o n l y  i n d u c e s  p a i n  d i r e c t l y ,  b u t  a l s o  i n d u c e s  c e n t r a l 
sensitization in the spinal cord, which indirectly contributes 
to pain as well. ROS which result from persistent abnormal 
aff er e n t in p u ts pr od u c ed in th e s pin a l c or d  can l ea d  to 
central sensitization, which in turn produces pain [17]. In 
other words, ROS have been suggested to contribute to the 
development and maintenance of neuropathic pain that can 
be relieved by systemic injection of ROS scavengers [16]. 
Therefore, an ROS scavenger such as vitamin C is sug-
gested to be neuroprotective by scavenging ex cess ROS 
[13,14]. Vitamin C is an extracellular and intracellular anti-
oxidant but also a major antioxidant in CSF [18], and its 
effect is concentration dependent [19]. Recently, previous 
reports showed that short-term intravenous administration 
of high-doses of vitamin C helped to reduce the pain in 
patients with PHN [5,6] and to treat patients with HZ [7]. 
    The dosage of vitamin C in the literatures has varied. 
It was reported that 2.5 g of intravenous vitamin C reduced 
pain in a 78-year-old man with PNH [5]. In addition, 15 
g of intravenous vitamin C was efficient in the treatment 
of two patients (females aged 67 and 53 years) with HZ 
[7]. In this case, intravenous administration of 4 g of vita-
min C was effective to reduce the pain in our patient with 
HZ.
    In conclusion, vitamin C may be an efficient adjuvant 
for multi-drug regimens to control pain in patients with 
H Z .  F o r m a l  s t u d i e s  a r e  r e q u i r e d  t o  d e t e r m i n e  w h e t h e r  
treatment with vitamin C may prove useful in patients with 
HZ.
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